share_log

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP: CORRESP

Aditxt | CORRESP：信函
美股SEC公告 ·  2024/06/08 10:17

Moomoo AI 已提取核心信息

Aditxt, Inc., a biotech company, has responded to comments from the U.S. Securities and Exchange Commission (SEC) regarding its Preliminary Proxy Statement filed on May 29, 2024. The SEC's feedback, dated June 6, 2024, prompted Aditxt to file Amendment No. 1 to the Preliminary Proxy Statement. The amendment includes a quantification of the proposed increase to the number of authorized shares of common stock and the range of the proposed reverse stock split. Additionally, Aditxt has revised its disclosures in response to the SEC's request for more information on the issuance of shares related to its Series A-1 Convertible Preferred Stock and has removed Proposal No. 6 concerning the issuance of shares of Series C-1 Convertible Preferred Stock from the amendment. These changes were made to comply with SEC regulations and to clarify the company's proposals to its shareholders.
Aditxt, Inc., a biotech company, has responded to comments from the U.S. Securities and Exchange Commission (SEC) regarding its Preliminary Proxy Statement filed on May 29, 2024. The SEC's feedback, dated June 6, 2024, prompted Aditxt to file Amendment No. 1 to the Preliminary Proxy Statement. The amendment includes a quantification of the proposed increase to the number of authorized shares of common stock and the range of the proposed reverse stock split. Additionally, Aditxt has revised its disclosures in response to the SEC's request for more information on the issuance of shares related to its Series A-1 Convertible Preferred Stock and has removed Proposal No. 6 concerning the issuance of shares of Series C-1 Convertible Preferred Stock from the amendment. These changes were made to comply with SEC regulations and to clarify the company's proposals to its shareholders.
生物科技公司Aditxt就其于2024年5月29日提交的初步代理声明，回应了美国证券交易委员会（SEC）的评论。 SEC在2024年6月6日发表的反馈意见促使Aditxt提交了《修正案1》。修正案包括对普通股授权股份提议增加数额的量化和提议反向股票分割的区间。此外，Aditxt在回应SEC对与其A-1可转换优先股有关股票发行的要求时调整了其披露，并从该修正案中删除了有关发行C-1可转换优先股的提案6。这些变更是为了遵守SEC监管要求并向公司股东澄清其提议。
生物科技公司Aditxt就其于2024年5月29日提交的初步代理声明，回应了美国证券交易委员会（SEC）的评论。 SEC在2024年6月6日发表的反馈意见促使Aditxt提交了《修正案1》。修正案包括对普通股授权股份提议增加数额的量化和提议反向股票分割的区间。此外，Aditxt在回应SEC对与其A-1可转换优先股有关股票发行的要求时调整了其披露，并从该修正案中删除了有关发行C-1可转换优先股的提案6。这些变更是为了遵守SEC监管要求并向公司股东澄清其提议。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Sana Biotechnology
    SANA
    -- 4.300
    Vir Biotechnology
    VIR
    -- 12.480
    Silo Pharma
    SILO
    -- 1.710
    Compass Therapeutics
    CMPX
    -- 1.860
    NLS Pharmaceutics
    NLSP
    -- 2.4100

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    特朗普即将重返政治舞台！特朗普提出的“美国优先”关税政策、加密货币政策以及对科技行业的影响，已成为市场关注的焦点。在此背景下，crypto、Tesla、AI板块的未来走势值得关注。 🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    询问策略师 - 川普的首日
    查看更多